After Hours
$
20.00
Change
+1.14 +6.04%
Volume
Volume 248,564
Feb 8, 2023, 7:48 p.m.
Quotes are delayed by 20 min
Previous close
$ 19.59
$ 18.86
Change
-0.73 -3.73%
Day low
Day high
$18.85
$20.17

52 week low
52 week high
$13.92
$28.18

Market cap
$1.59B
Average volume
759,295
P/E ratio
N/A
Rev. per Employee
$275,583
EPS
-0.96
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on MYGN
-
Myriad Genetics upgraded to outperform from market perform at Raymond James
- Tomi Kilgore
-
Thematic ETFs Look Tempting. Just Say No.
- Barron's Online
-
Myriad Genetics initiated at market perform at Raymond James
- Tonya Garcia
-
Myriad Genetics Stock Is Jumping. Earnings Were Great.
- Barron's Online
-
Myriad Genetics stock price target cut to $14 from $17 at J.P. Morgan
- Tomi Kilgore
-
Myriad Genetics Stock Is Tanking After Earnings. The CEO Is Out.
- Barron's Online
-
Nio Stock Is Soaring, Myriad Genetics Jumps, as the Dow Holds Its Ground
- Barron's Online
-
Uber Stock, Shake Shack Are Falling as the Dow Chugs Ahead Again
- Barron's Online
-
Myriad Genetics Stock’s Wild Ride Will Continue, Analyst Says
- Barron's Online
-
Myriad Genetics downgraded to underperform from neutral at BofA Merrill Lynch
- Tomi Kilgore
-
Myriad Executives Sold Stock Before Shares Plunged
- Barron's Online
-
Myriad Genetics Runs Into Trouble With the F.D.A.
- Barron's Online
-
The Dow Is Tumbling Because Stocks Can’t Ignore the Bond Market Anymore
- Barron's Online
-
Myriad Genetics Craters on Weak Earnings, FDA Scrutiny
- Barron's Online
- Loading more headlines...
Analyst Ratings
-
Benzinga's Top Upgrades, Downgrades For March 21, 2018
- Benzinga.com
-
Goldman Sachs Models 22% Downside To Myriad Genetics
- Benzinga.com
-
Benzinga's Top Upgrades, Downgrades For January 5, 2018
- Benzinga.com
Other News on MYGN
-
CareDx: Organ Transplant Business Falters In Q3
- Seeking Alpha
-
Myriad Genetics: All You Need To Know About Q3 Earnings
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Myriad Genetics, Inc. (MYGN) Q3 2022 - Earnings Call Transcript
- Seeking Alpha
-
MNSO and CLEU among mid-day movers
- Seeking Alpha
-
Myriad Genetics Q3 2022 Earnings Preview
- Seeking Alpha
-
OncoCyte: FDA's Regulatory Arm Might Pressure This Microcap
- Seeking Alpha
-
Myriad: Trying To Find Its Footing In An Evolving Industry
- Seeking Alpha
-
Invitae Busted Business Model Offers A Tactical Opportunity
- Seeking Alpha
- Loading more headlines...
Press Releases on MYGN
-
Myriad Genetics Reports Third Quarter Financial Results
- GlobeNewswire
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com